Liver transplantation in human immunodeficiency virus–infected patients: Procoagulant, but is antithrombotic prophylaxis required?

P. Thomas Cherian, Wesal Alrabih, Abdel Douiri, Alberto Quaglia, Michael A. Heneghan, John O'Grady, Mohamed Rela, Nigel D. Heaton – 17 October 2011 – Liver transplantation (LT) for human immunodeficiency virus (HIV)–positive recipients with end‐stage liver disease has become an accepted practice. However, because these patients are increasingly being recognized as prothrombotic, we reviewed their posttransplant thrombotic complications.

Outcome of post–liver transplant ischemic and nonischemic biliary stenoses treated with percutaneous interventions: The bologna experience

Emanuela Giampalma, Matteo Renzulli, Cristina Mosconi, Giorgio Ercolani, Antonio Daniele Pinna, Rita Golfieri – 17 October 2011 – In liver transplantation (LT), biliary strictures (BSs) are among the most common complications. The aim of this study was to evaluate the efficacy of percutaneous treatments in the management of post‐LT BSs. Between 1999 and 2007, 48 patients underwent percutaneous treatments for posttransplant BSs.

The protease inhibitor, GS‐9256, and non‐nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C

Stefan Zeuzem, Peter Buggisch, Kosh Agarwal, Patrick Marcellin, Daniel Sereni, Hartwig Klinker, Christophe Moreno, Jean‐Pierre Zarski, Yves Horsmans, Hongmei Mo, Sarah Arterburn, Steven Knox, David Oldach, John G. McHutchison, Michael P. Manns, Graham R. Foster – 17 October 2011 – Tegobuvir (GS‐9190), a non‐nucleoside nonstructural protein (NS)5B polymerase inhibitor, and GS‐9256, an NS3 serine protease inhibitor, individually have activity against hepatitis C virus (HCV) genotype 1.

Hepatitis E virus (HEV)‐specific T‐cell responses are associated with control of HEV infection

Pothakamuri Venkata Suneetha, Sven Pischke, Verena Schlaphoff, Jan Grabowski, Paraskevi Fytili, Anna Gronert, Birgit Bremer, Antoaneta Markova, Jerzy Jaroszewicz, Christoph Bara, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer – 17 October 2011 – Hepatitis E virus (HEV) infection is usually self‐limited but may lead to acute hepatitis and rarely to fulminant hepatic failure. Persistent HEV infections have recently been described in organ transplant recipients receiving immunosuppressive medications, suggesting that HEV is controlled by adaptive immune responses.

Thrombocytopenia, splenomegaly, and portal blood flow in patients who have undergone liver transplantation for cirrhosis

Daniel Eyraud, Benjamin Granger, Christian Ionescu, Silvia Fratéa, Sabine Darnat, Jean‐Christophe Vaillant, Jean‐Michel Siksik, Laurent Hannoun, Pierre Coriat – 17 October 2011 – The platelet count (PC), the spleen size (SS), and the portal blood flow (PBF) have been independently studied in the perioperative period after orthotopic liver transplantation (OLT) for cirrhosis, but these parameters have not been described and analyzed in combination.

Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: Role of biopsy

Thomas Sersté, Vincent Barrau, Violaine Ozenne, Marie‐Pierre Vullierme, Pierre Bedossa, Olivier Farges, Dominique‐Charles Valla, Valérie Vilgrain, Valérie Paradis, Françoise Degos – 17 October 2011 – Liver macronodules, ranging from benign to low‐grade or high‐grade dysplastic nodules (LGDNs/HGDNs) and hepatocellular carcinoma (HCC), may develop during chronic liver diseases (CLDs).

A phase 2, randomized, double‐blind, placebo‐controlled study of GS‐9450 in subjects with nonalcoholic steatohepatitis

Vlad Ratziu, Muhammad Y. Sheikh, Arun J. Sanyal, Joseph K. Lim, Hari Conjeevaram, Naga Chalasani, Manal Abdelmalek, Anezi Bakken, Christophe Renou, Melissa Palmer, Robert A. Levine, B. Raj Bhandari, Melanie Cornpropst, Wei Liang, Benjamin King, Elsa Mondou, Franck S. Rousseau, John McHutchison, Mario Chojkier – 17 October 2011 – In nonalcoholic steatohepatitis (NASH), the extent of hepatocyte apoptosis correlates with disease severity. Reducing hepatocyte apoptosis with the selective caspase inhibitor GS‐9450 has a potential for altering the course of the liver disease.

Subscribe to